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Summary We investigated the pharmacokinetic profile and the efficacy of ondansetron (day 1) given as 16 mg
suppository once a day, as compared with ondansetron 8 mg tablets twice daily, in patients receiving
moderately emetogenic chemotherapy. The study was primarily aimed at investigating the pharmacokinetics
and was part of a large multinational, randomised, double-blind, double-dummy efficacy trial. Pharmacokinetic
data were obtained in a total of 20 patients, 11 of whom had received a suppository containing ondansetron,
and nine patients had received the oral formulation. The median area under the plasma concentration curve
(AUC) obtained with the oral formulation was 226 ng ml-lh-' (range 91-750), and the median maximum
plasma level (Cmax) was 50.5 ng ml-' (range 24.7-199.6) after a dose of 8 mg. For the ondansetron
suppository the median AUC was 140 ng ml-h-1 range (77-405) and the median Cmax was 17.1 ng ml-l
(range 13-48.3) after a dose of 16 mg. The systemic exposure after correction for the dose difference after the
suppository was on average 70% lower than after the tablet. The median time to reach the maximum level
(Tmax) was 60 min (range 28- 120) with the oral formulation and 209 min (range 90-420) with the suppository.
For both the tablet and suppository, there was no apparent relationship between either Cmax or AUC, and
efficacy. Although the patient numbers were too small for a formal exposure-response relationship to be
derived, the slightly poorer pharmacokinetic performance of the suppository did not appear to be associated
with a lessening of control of emesis following chemotherapy. The study demonstrates that the
pharmacokinetic analysis of a once-daily 16 mg ondansetron suppository results in appropriate plasma
concentrations and AUC, and that this rectal formulation is effective in the protection against nausea and
vomiting associated with cyclophosphamide chemotherapy. This formulation will provide a useful alternative to
the currently available oral formulation.
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Nausea and vomiting are the most distressing aspects of
cancer chemotherapy (Coates et al., 1983). The prevention
and treatment of these symptoms was greatly improved with
the development of selective 5HT3 receptor antagonists,
which yield control of nausea and vomiting in more than
70% of patients treated with highly emetogenic chemother-
apy during the first cycle of chemotherapy (Kaasa et al.,
1990; Bonneterre et al., 1990; Marschner et al., 1991). The
5HT3 receptor antagonist ondansetron is rapidly absorped
after oral administration and has an absolute bioavailability
of approximately 60%. However, oral administration may
not be suitable for all patients, especially those who have
difficulty in swallowing, or in the outpatient setting in
patients whose emesis is poorly controlled. In such cases,
an alternative formulation such as a suppository may be
useful. Based on pharmacokinetic data from ondansetron
suppositories in healthy volunteers, the pharmacokinetic
profile and the efficacy of ondansetron given as a 16 mg
suppository once a day, as compared with ondansetron 8 mg
tablets twice daily, was investigated in patients receiving
moderately emetogenic chemotherapy. This study was part of
a multicentre, multinational, randomised, double-blind,
double-dummy, parallel group study, that was primarily
aimed at investigating the efficacy, safety and tolerability of
the suppository formulation.
Patients and methods
Clinical protocol
Eligible patients were aged > 18 years, receiving their first
course of chemotherapy comprising cyclophosphamide at an
intravenous dose of > 500 mg m-2 given over a period of up
to 2 h, alone or in combination with other cytotoxic agents.
Exclusion criteria were concomitant highly emetogenic
cytotoxics such as cisplatin, dacarbazine and ifosfamide;
severe concurrent illness other than neoplasia or with other
aetiologies for vomiting; medications with known or potential
antiemetic activity; vomiting or retching or moderate or
severe nausea in the 24 h before the first dose of the study
drug; any condition that could affect absorption of the drug
from a suppository, including but not limited to diarrhoea,
malabsorption syndrome, rectal carcinoma and an anus
praeter. Abdominal or pelvic irradiations within 48 h or
scheduled to receive such radiotherapy during the study
period, and moderately or severely impaired hepatic function
were also exclusion criteria. Approval of the Ethics
Committee of the participating hospitals was obtained. All
patients gave informed consent.
Patients were monitored by trained staff nurses in the
hospital for the first 24 h following the start of the
cyclophosphamide infusion, and daily by diary cards during
the 3 day study period. The timing and number of retching
and vomiting episodes were recorded as well as nausea
experienced each day as assessed on a four-point graded scale
(no nausea, mild nausea, i.e. not interfering with normal daily
life; moderate nausea, interfering with normal daily life;
severe nausea, bedridden as a result of nausea) and global
satisfaction as assessed on a 100 mm visual analogue scale
(which ranged from 'not satisfied' at 0 mm to 'completely
satisfied' at 100 mm) each day before retiring to bed. All data
were cross-checked with the patient at the time of the end of
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study visit, which was between 5 and 14 days following the
initial study drug administration. The intake of the study
medication was verified by a direct count of any remaining
study drug.
For the efficacy evaluation of the multicentre study a
worst-day analysis (days 1-3) on emesis alone or nausea
alone was used. For the purpose of this cohort, analysis of
the pharmacokinetic profile and accompanying protection,
the efficacy evaluation, was based on the protection obtained
on day 1.
Antiemetic treatment
Patients were randomised (1:1) to treatment with one of the
following:
(a) 8 mg ondansetron orally b.d. (ondansetron as the
hydrochloride dihydrate) plus placebo suppository once
daily;
(b) 16 mg ondansetron suppository once daily (ondansetron
as the free base) plus placebo tablets b.d.
Treatment was begun 2 h before initiation of cyclopho-
sphamide chemotherapy with dosing of the suppository and
the first tablet concomitantly.
Sample handling
Before ondansetron treatment commenced, patients had an
additional line inserted in the arm opposite the one to be
used for the administration of chemotherapy drugs. A blood
sample for a baseline assessment was taken just before the
first rectal or oral dose of ondansetron (t =0). Further blood
samples for the ondansetron assay were taken 0.5, 1, 1.5, 2,
2.5, 3, 4, 5, 7, 8 and between 9 and 12 h after the first rectal
or oral dose of ondansetron. The actual time of the
administration of the study medication and blood samples
was recorded. Blood samples were centrifuged at 1500 g for
10 min and the plasma transferred to screw-top polypropy-
lene tubes and frozen at -20°C immediately after collection.
The sample tubes containing the plasma were labelled with
nominal time and date. All samples were shipped on dry ice
to the Pharmacy Department of the Slotervaart hospital and
kept frozen until required for analysis.
Analytical methodology
Samples were analysed according to the method described
previously (Colthup et al., 1991). Briefly, plasma samples were
mixed with 200 jM of 25% (v/v) acetic acid in water. After the
samples were loaded on Bakerbond Cyano Solid Phase
Extraction Columns, the columns were washed with water
(2 ml), acetonitrile (2 ml), and 0.1% (v/v) triethylamine in
acetonitrile (0.4 ml). Next ondansetron was eluted with 500 PI
of 1% (v/v) triethylamine in acetonitrile. The elutes were dried
by vacuum at 45°C and the residues were redissolved in 150 jl
of acetonitrile. An aliquot of 100 ll was subjected to
chromatography. Chromatography was performed using a
3 jgm Spherisorb Si (100 x 4.6 mm) analytical column and a
mobile phase composed ofacetonitrile: 0.025 M sodium acetate
buffer pH 4.2 (40:60, v/v). UV detection at 305 nm was
employed. The validated concentration range is 1.5-
20 ng ml-'. Samples beyond this concentration have been
diluted with drug-free human plasma obtained from the
Central Laboratory for Blood Transfusion Services, Amster-
dam. The values for accuracy and precision were within
accepted criteria for bioanalytical research (Shah et al., 1992).
The peak purity of the ondansetron chromatographic peak
was inspected in a number of selected plasma samples by
using a model 1OOOS photodiode array detector (Kratos, NJ,
USA) instead of a fixed wavelength UV detector. UV spectra
were sampled every 0.1 min. Further spectral data analyses
were performed on an IBM-compatible computer provided
with the Lab Calc software package (Galactic Industries,
Salem, NH, USA).
Pharmacokinetic evaluation
The route of administration was unknown at the date of
determination of the plasma levels. The following pharma-
cokinetic parameters were assessed: the maximum plasma
level (Cmax), the time to reach the maximum level (Tmax) and
the area under the plasma concentration curve (AUC). The
parameters Cmax and Tmax were graphically derived from the
plasma concentration time curves. The AUCs were calculated
by the trapezium rule and were calculated over the time
interval from the first sample (t=0 h) to the sample collected
at 9-12 h after administration.
Statistical analysis
The differences in the pharmacokinetic parameters were
evaluated with the non-parametric Mann-Whitney rank-
sum text. A P-value of<0.05 was considered statistically
significant.
Results
Patient characteristics
Twenty patients took part in the pharmacokinetic study. The
median age was 47 years (range 30-70). Eleven patients were
randomised to receive a suppository containing ondansetron
and nine patients were randomised to receive the oral
formulation.
Seventeen female patients received 5-fluorouracil 500 mg
m-2, epirubicin 50 or 90 mg m-2, cyclophosphamide 500 mg
ml-2 (FEC) or doxorubicin 60 or 75 mg m-2, cyclopho-
sphamide 600 or 1000 mg m-2 (AC) chemotherapy for either
locally advanced or metastatic breast cancer. Of these, eight
patients had received the oral formulation, and nine patients
had received ondansetron per suppository. Patient character-
istics and dosages of chemotherapy were well balanced
between these two groups (data not shown). Two male
patients with small-cell lung cancer were treated with
cyclophosphamide 1000 mg m-2, doxorubicin 45 mg m-2,
etoposide 100 mg m-2, day 1 (CDE) both of whom received
a suppository containing the drug. The third male patient
was treated with cyclophosphamide 750 mg m-2, and
doxorubicin 50 mg m-2 for non-Hodgkins lymphoma, and
received the oral tablet formulation.
Pharmacokinetic parameters and emetic protection
For the purpose of plotting median plasma concentrations,
the time associated with the blood sample due between 9 and
12 h after the dose was depicted as 12 h. In the estimation of
the individual AUC value, the actual time of sample
collection was used.
Quantification of ondansetron in the samples from two of
the patients receiving active oral treatment was not possible
due to co-eluting interferences. The predose sample of these
two patients was free of interfering peaks. The presence of
these co-eluting interferences in the samples was confirmed by
the use of the UV photodiode array (UV-PDA) detector.
Although the interfering peak had a retention time close to
ondansetron, the UV spectrum was distinct from that of
ondansetron. In the UV spectra taken at the rising slope of
the peak, we demonstrated the presence of ondansetron,
whereas at the apex and descending slope the interference was
abundantly present. No interferences could be detected in the
UV spectra of the other patients. The nature and origin of
the interfering compounds could not be determined. No
ondansetron was detectable in the samples from one patient
scheduled to receive the active suppository. This finding is
not consistent with previous findings in healthy volunteers
and other patients. The first recorded bowel movement in this
patient was approximately 9l/2 h post dose and it is therefore
unlikely that the suppository was voided before any
significant ondansetron absorption having occurred. It wasPharmacokineics and efficacy of a once-daily ondanestron suppository
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considered that this patient had not administered the
suppository properly and the patient was excluded from the
pharmacokinetic assessment.
The Cmax and AUCs of ondansetron varied widely between
patients (Table I). Relatively high levels (> 100 ng ml-') were
reached in three patients who received the oral formulation.
In these patients the peak levels were reached early in the
course of the concentration-time curves. By examination of
the medical files it was verified that these patients had not
received additional ondansetron medication in the first 24 h
period. Figure 1 shows the median plasma ondansetron
concentrations. The median area under the plasma concen-
tration curve (AUC) obtained with the oral formulation was
226 ng ml-'h-' (range 91-750), and the median maximum
plasma level (Cm,,) was 50.5 ng ml-' (range 24.7-199.6). For
the ondansetron suppository the median AUC was
140 ng ml-'h-' range (77-405) and the median Cma,, was
17.1 ng ml-' (range 13-48.3). The difference between the
dose-corrected AUC values after administration of the oral
formulation and the suppository revealed statistical signifi-
cance (P<0.01). The Cma,, value after the tablet was
significantly higher than after the suppository (P<0.01).
The ratio of the median AUC values after rectal and oral
administration after correction for the difference in dose
illustrates that the systemic availability after rectal adminis-
tration in this group of patients is approximately 70% lower
than after oral administration. The median time to reach the
maximum level (TmaX) was 60 min (range 28-120) with the
oral formulation, and 209 min (range 90-420) with the
suppository (P<0.01). Table I also shows the protection
against emesis and nausea that was obtained and satisfaction
scores for the individual patients. Although the numbers are
too small for a formal exposure-response relationship to be
derived, there was no apparent relationship between either
Cmax or AUC and efficacy.
Discussion
Cyclophosphamide-containing chemotherapy regimens are
frequently given as outpatient treatment for various
malignancies. Nausea and vomiting are frequent side-effects
resulting from this type oftherapy and may persist for several
days. Therefore, effective antiemetic treatment that is simple
and convenient to administer is essential to the supportive
management of these patients in an outpatient setting. Oral
administration of antiemetics may be the route of choice in
these situations. However, the tablet formulation may not be
suitable for all patients, especially those who have difficulty in
swallowing or in patients whose emesis and nausea is poorly
controlled. The intravenous route of administration is not
ideal for outpatient usage because it requires medical
professional intervention. The suppository formulation
provides a useful alternative in these cases. Consequently,
an ondansetron suppository has been developed for the
management of chemotherapy- and radiotherapy-induced
emesis.
The plasma ondansetron concentration-time profiles from
the ten evaluable patients receiving a 16 mg suppository once
daily were generally lower than the median profile (although
essentially contained within the range of concentrations)
observed in the patients receiving the oral formulation. The
systemic exposure after the rectal administration was,
corrected for the dose difference, on average 70% lower
than after oral administration. The difference was statistically
significant. The median time taken for the patients to attain
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Figure 1 Median plasma ondansetron concentrations. ---,
16mg ondansetron suppository; -0-, 8mg ondansetron tablet.
Table 1 Pharmacokinetic parameters and emetic responses following ondansetron treatment on day 1
Pharmacokinetic results Clinical results
AUC Cm. T..x Protection Satisfaction
(ng ml -'h-1) (ng ml -') (min) Emetic episodes Nausea (mm)
Route ofadministration: tablets (dose=8 mg)
91 24.7 60 0 No 100
750 199.6 28 0 No 100
364 134.2 30 0 Mild 100
226 50.5 60 0 Mild 100
225 34.4 85 2 Severe 10
616 121.0 120 0 No 100
176 46.3 90 3 Severe 0
Median 226 50.5 60
Range 91-750 24.7- 199.6 28-120
Route ofadninistration: suppository (dose= 16 mg)
77 15.2 90 3 Severe 0
142 16.4 307 0 Mild 80
138 14.6 231 0 Moderate 70
224 31.0 180 >3 Severe 0
125 13.0 299 0 Mild 100
405 48.3 300 0 No 100
123 16.1 186 0 No 100
160 21.1 420 >3 Severe 30
200 36.5 180 >3 Severe 5
121 17.7 94 1 Mild 90
Median 140 17.1 209
Range 77-405 13-48.3 91 -420Pharmacokinetics and efficacy of a once-daily ondansetron suppository
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maximum plasma ondansetron concentrations after rectal
administration of the drug was 31/2 h. The suppository
concentration-time profile (Figure 1) shows a prolonged
plateauing of concentration at or near the maximum
concentration, which points at prolonged duration of
absorption. The median Cmax and AUC values for the
tablets in the patients in this study are similar to, or slightly
greater than those obtained in other studies (Hsyu et al.,
1994).
For both the tablet and suppository, there was no
apparent relationship between either the maximum concen-
tration achieved or systemic exposure (AUC) and efficacy in
this group of patients. This observation is in accordance with
previous findings (Pritchard, 1992) that there is no clear
pharmacokinetic -pharmacodynamic relationship within the
range of Cmax, 4 h concentration and AUC observed in this
study. A similar finding has been reported (Cupissol et al.,
1993) for another 5-HT3 antagonist, granisetron, despite
greater interpatient variability in AUC than seen here. The
lack of any apparent relationship between exposure and
efficacy may, however, be due in part to the small patient
numbers involved and the relatively heterogenous nature of
the patient groups. The lower plasma levels obtained with the
suppository in some subjects in this study did not appear to
be associated with a lessening of control of emesis following
chemotherapy.
This study demonstrates that the pharmacokinetic analysis
of a once-daily 16 mg ondansetron suppository results in
plasma concentrations and AUC that are adequately effective
against nausea and vomiting associated with cyclopho-
sphamide chemotherapy. This formulation will provide a
useful alternative to the currently available oral formulation.
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